Status:

TERMINATED

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

Lead Sponsor:

City of Hope Medical Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Estrogen Receptor-positive Breast Cancer

Invasive Ductal Breast Carcinoma

Eligibility:

FEMALE

Phase:

NA

Brief Summary

This pilot clinical trial studies biomarkers in tissue samples from patients with newly diagnosed breast cancer treated with zoledronic acid (ZA). Studying samples of tumor tissue in the laboratory fr...

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate 14 tumor biomarkers of growth and metastasis (10 by microarray and 4 by RT-PCR) for change in response to ZA. SECONDARY OBJECTIVES: I. To evaluate 30 measures of ...

Eligibility Criteria

Inclusion

  • Postmenopausal women
  • Diagnosis of early stage, invasive ductal carcinoma (for which a lumpectomy or mastectomy is planned prior to systemic therapy)
  • Estrogen receptor (ER)/progesterone receptor (PR) positive tumor (as confirmed by City of Hope Pathology Department if done on the outside) or
  • Biopsy proven ER/PR positive tumor
  • Ability to provide informed consent

Exclusion

  • Tumor that lacks both estrogen and progesterone receptors
  • Patients who will receive neoadjuvant therapy prior to definitive surgery
  • Bisphosphonate therapy currently or within the past 12 months
  • Regular use of anti-inflammatory agents, with the exception of a baby aspirin regimen per principal investigator's (PI's) discretion
  • Renal impairment as determined by a creatinine clearance \< 60 ml/min as calculated by the Cockcroft-Gault formula using the patient's actual weight
  • Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures
  • Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)

Key Trial Info

Start Date :

September 14 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2015

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT01409811

Start Date

September 14 2012

End Date

February 1 2015

Last Update

May 8 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

City of Hope Medical Center

Duarte, California, United States, 91010